Screening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States
|
|
- Louisa Curtis
- 6 years ago
- Views:
Transcription
1 478826JMHXXX / American Journal of Men s HealthLim et al. Article Screening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States American Journal of Men s Health 7(4) The Author(s) 2013 Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / jmh.sagepub.com Sian Yik Lim, MD 1, Joon Hee Lim, MD 1, Dan Nguyen, BA 1, Rie Okamura, BA 1, Hoda Mojazi Amiri, MD 1, Michael Calmes, MD, MBA 1, and Kenneth Nugent, MD 1 Abstract Osteoporosis in men is an underrecognized and undertreated condition. Despite the National Osteoporosis Foundation recommending osteoporosis screening in men aged 70 years and older since 2008, screening rates in the United States remain undefined. In our study, we analyzed dual-energy X-ray absorptiometry (DXA) screening rates in a primary care setting. Overall, screening rates were low (11.3%). Although there was an increase with age in both the 10-year osteoporotic and 10-year hip fracture probabilities, no association was found between increased age and bone mineral density testing using DXA. Only 23.2% of patients were prescribed bone protective treatments. The performance of DXA screening strongly predicted prescription of bone protective treatment. Increased age raised the likelihood of bone protective treatment prescriptions; however, smokers were less likely to be prescribed these medications. As the population in the United States ages, an increased awareness of this major public health problem is warranted. Keywords osteoporosis, dual-energy X-ray absorptiometry, older men Osteoporosis in men is an underrecognized and undertreated condition. The National Health and Nutrition Examination Survey ( ) data reported that 2% (800,000) of men aged 50 years and older have osteoporosis, and 30% (11.8 million) have osteopenia (Looker, Melton, Harris, Borrud, & Shepherd, 2010). By 2020, the number of patients with osteoporosis will increase to 3.3 million (Lim, Hoeksema, & Sherin, 2009). In 2005, the treatment of osteoporotic fractures cost 17 billion dollars in the United States, with men accounting for 25% of this cost. The cost is expected to increase in the near future as the population in the United States ages (Burge et al., 2007). Osteoporotic fractures in men are associated with higher mortality and morbidity as compared with women (Bliuc et al., 2009). Therefore, osteoporosis in men is a public health problem that requires immediate attention. The National Osteoporosis Foundation (NOF) guidelines published in 2008 recommended osteoporosis screening in men aged 70 years and older (NOF, 2008). Although the U.S. Preventive Services Task Force (2011) concluded that there is insufficient evidence to assess the balance of benefits and harms of screening for osteoporosis in men, screening in men aged 70 years and older is supported by other organizations, such as the American College of Preventive Medicine (Lim et al., 2009), the Endocrine Society (Watts et al., 2012), and the International Society of Clinical Densitometry (Lewiecki et al., 2004). The American College of Physicians recommends that physicians perform individualized assessment of risk factors for osteoporosis in older men periodically, with age 70 years and older being one of the factors that increase the risk of osteoporosis (Qaseem et al., 2008). Since publication of guidelines by the NOF in 2008, the screening rates in men aged 70 years and older in the United States remain undefined. In our study, we analyzed the screening rates for osteoporosis in men aged 70 years and older at a university-based primary care setting in the United States. Materials and Methods We performed a retrospective chart review of patients seen at Texas Tech University Health Sciences Center Internal Medicine Clinic between January 1, 2011, and 1 Texas Tech University Health Sciences Center, Lubbock, TX, USA Corresponding Author: Sian Yik Lim, Texas Tech University Health Sciences Center, Internal Medicine, th Street, Lubbock, TX 79430, USA. sian.yik.lim@ttuhsc.edu
2 Lim et al. 351 January 1, A registry of male patients aged 70 years and older seen during that period was generated from electronic medical records. These records were screened by researchers for exclusion criteria. We excluded patients who were one time hospital discharge followups, one time preoperative evaluation visits, and patients not seen two or more times over a 3-year period (April 1, 2009, to April 1, 2012). We tried to include only patients who considered our clinic as their primary care provider. Electronic medical records of patients included in the study were reviewed for demographic data, clinical information, dual-energy X-ray absorptiometry (DXA) status, and prescriptions for bone protective treatments (defined as calcium supplements, vitamin D supplements, biphosphonates, teriparatide, calcitonin, and testosterone supplements). Data were collected using standardized data collection forms. The 10-year osteoporotic and hip fracture probabilities of individual patients were calculated using the World Health Organization Fracture Risk Assessment Tool. Analysis of the effect of increasing age on bone mineral density (BMD) testing was performed using chi-square test for trend with patients divided into age groups of 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, and 95 to 99 years. Pearson s correlation was used to analyze correlation of age with 10-year osteoporotic and hip fracture probabilities. To analyze the predictors for bone protective treatments, Pearson chi-square tests were used initially to calculate individual odds ratios (ORs) for each predictor. Factors that had a p value of less than.25 were selected to be further analyzed using multivariate logistic regression analysis. This study was approved by institutional review board at Texas Tech University Health Sciences Center. Results Three hundred and forty-one male patients aged 70 years and older were seen in the clinic during the study period; 310 patients were included in the study. Table 1 shows the baseline characteristics in our study population. Thirty-five patients (11.3%, 95% confidence interval [CI] = ) received osteoporosis screening using DXA scans. Among those screened, BMD testing indicated that 8 patients (22.9%) were osteoporotic, 22 patients (62.9%) had low bone mass, and 5 patients (14.3%) had normal BMD. Table 2 shows the proportion of patients in each age group that received screening for osteoporosis using DXA scans. In the 70 to 74 years age group, 9.9% were screened. The proportion of patients screened with DXA scans decreased in the 75 to 79 years age group (8.2%), but then increased in the 80 to 84 years (16.7%) and 85 to 89 years age groups (18.9%). No patient aged 90 years and older was screened. No significant Table 1. Baseline Characteristics for Study Population. Median age, years (range) 76 (70-98) Race, n (%) Whites 189 (61) Hispanics 73 (23.5) African American 22 (7.1) Asian 2 (0.6) Other 24 (7.7) Mean body mass index, kg/m 2 (range) 27.7 (15-46) Marital status, n (%) Married 197 (63.5) Single/divorced/separated/other 113 (36.5) Number of comorbid conditions, n (%) 0 to 3 37 (11.9) 4 to 5 76 (24.5) 6 or more than (63.5) Number of medications taken, n (%) 0 to 3 20 (7) 4 to 6 42 (14) 7 or more than (80) Other comorbid conditions, n (%) Smoker 31 (10) Rheumatoid arthritis 7 (2.3) History of fracture 20 (6.5) Prolonged glucocorticoid use 9 (2.9) association was found between increasing age and BMD testing (p =.299). Results from the assessment of baseline 10-year osteoporotic fracture and 10-year hip fracture risk in our study population are shown in Table 3. The medians of the 10-year osteoporotic and hip fracture probabilities in the 70 to 74 years age group were 5.6% (range = 2.0% to 14.0%) and 1.4% (range = 0.2% to 5.3%). The medians of the 10-year osteoporotic and hip fracture probabilities peaked in the 90 to 94 years age group at 9.4% (range = 5.7% to 10.0%) and 6.1% (range = 3.0% to 7.9%), respectively. Age was positively correlated with the 10-year hip fracture probability (r =.68, p <.0001) and the 10-year osteoporotic fracture probability (r =.53, p <.0001). Seventy-two patients were prescribed bone protective treatments. This represented 23.2% of the study population. Most patients were taking calcium (14.2%) and vitamin D supplements (21.0%); 3% of the patients were taking biphosphonates. The OR for age was 1.09 (95% CI = ) for each 1-year increase in age, and analysis of individual risk factors is shown in Table 4. Binary logistic regression demonstrated that BMD screening with DXA for osteoporosis was a strong predictor of receiving bone protective treatment (OR = 6.2; 95% CI = ). Other predictors for bone protective treatment include increasing age, but smokers were less likely to receive prescriptions of bone protective treatments (Table 5).
3 352 American Journal of Men s Health 7(4) Table 2. Patients Screened for Osteoporosis Using DXA. Age group Number of patients Number of patients screened Percentage of patients screened % confidence interval Note. DXA = dual-energy X-ray absorptiometry. Table 3. Baseline Risk in Study Population Based on Calculation of the World Health Organization Fracture Risk Assessment Tool Score. Age group Discussion Median 10-year osteoporotic fracture risk (range) Median 10-year hip fracture risk (range) ( ) 1.4 ( ) ( ) 2.5 ( ) ( ) 4.3 ( ) ( ) 5.0 ( ) ( ) 6.1 ( ) ( ) 6.1 ( ) Osteoporosis in men is an underrecognized and undertreated condition. Although well recognized in women, there is a lack of awareness among medical professionals and the public that osteoporosis also affects older men (Rao, Budhwar, & Ashfaque, 2010). Several studies have shown that osteoporosis screening rates in older men are low. A study in Canada showed that screening rates for osteoporosis in older men was 19.1% (Cheng & Green, 2008). Osteoporosis in men is undertreated as compared with women (Beaupre, Majumdar, Dieleman, Au, & Morrish, 2012; Shibli-Rahhal, Vaughan-Sarrazin, Richardson, & Cram, 2011). However, since the publication of the NOF guidelines in 2008 recommending DXA screening in men aged 70 years and older, there are little data regarding screening rates of older men in the United States. In our study, screening rates for osteoporosis using DXA scans in men aged 70 years and older were low at 11.3%. The screening rates at our center are comparable with the rates in Canada (Cheng & Green, 2008) and with a recent study performed in the United States (Alswat & Adler, 2012) in which screening rates in men were 19.1% and 18.4%, respectively. Only 23.2% of patients aged 70 years and older were prescribed bone protective treatments in our study. Our study reinforces the fact that osteoporosis in men remains underrecognized and undertreated. In our study population, the baseline 10-year osteoporotic fracture and hip fracture risk increased with age. This is expected since both men and women have an exponential rise in fracture incidence as they age, although in men the increase occurs 10 years later than in women (van Staa, Dennison, Leufkens, & Cooper, 2001). Although there was a general trend that showed an increase in the proportion of patients screened from the 70 to 74 years age group to the 85 to 89 years age group, this trend was not statistically significant. No patient aged 90 years and older was screened. The fact that there was no association between increasing age and screening rates could be attributed to the small sample size in our study, and larger studies are needed to clarify this. In extremes of age, individualized decisions by physicians taking into account the patient s life expectancy and personal values may be more useful than age-based screening recommendations to avoid unnecessary DXA scans in older men. The performance of DXA scans was a strong predictor for prescription of bone protective treatments. Increasing age was also associated with increased bone protective treatment rates, but smokers were less likely to be prescribed bone protective treatment in our study. The observation that smokers are less likely to receive preventive health care has been demonstrated in several studies on the utilization of cancer screening services (Lagerlund, Sparen, Thurfjell, Ekbom, & Lambe, 2000). Our study suggests that this may occur in noncancer prevention efforts also, and smokers may represent an important target group for improvement of preventive health care programs. Several barriers are noted in osteoporosis screening in men aged 70 years and older in the United States. Because osteoporosis has been traditionally considered a women s health issue, awareness of its importance among the public and physicians remains low (Adler, 2006). Furthermore, Medicare coverage in the United States regarding DXA scans in men is limited to patients on prolonged glucocorticoids, patients with hyperparathyroidism or osteoporosis, and those with vertebral abnormalities on X-ray (Centers for Medicare & Medicaid Services, 2012). Although there are studies
4 Lim et al. 353 Table 4. Unadjusted Odds Ratio of Factors Affecting Bone Protective Prescription. Factor OR (95% CI) p Non-Caucasian 1.0 Caucasian 1.3 ( ).393 Age 1.09 ( ) Glucocorticoid use 0.4 ( ).398 Rheumatoid arthritis 0.5 ( ).558 History of fracture 2.9 ( ).022 Antiandrogen use 3.3 ( ).396 Smoker 0.1 ( ).023 Osteoporosis screening with DXA 6.6 ( ) <.0001 COPD 0.9 ( ).880 CKD stage ( ).213 GERD 0.7 ( ).223 Dysphagia 2.0 ( ).342 Alcohol consumption, less than two drinks per day 1.3 ( ).745 Note. OR = odds ratio; CI = confidence interval; DXA = dual-energy X-ray absorptiometry; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; GERD = gastroesophageal reflux disease. Factors with p value less than.25 were selected and analyzed using multivariate logistic regression analysis. Table 5. Logistic Regression-Predictors of Bone Protective Treatment Prescriptions. Factors OR (95% CI) Osteoporosis screening with DXA 6.1 ( ) Increasing age 1.08 ( ) Smokers 0.08 ( ) History of fracture 2.5 ( ) GERD 0.5 ( ) CKD stage ( ) Note. OR = odds ratio; CI = confidence interval; DXA = dual-energy X-ray absorptiometry; GERD = gastroesophageal reflux disease; CKD = chronic kidney disease. noting the cost effectiveness of screening in older men (Schousboe et al., 2007), data in men need confirmation, clarity, and validity to convince payers, including Medicare, that at some determined age screening of men has to be funded if effective treatment is to be offered. Our study has several limitations. This study was performed at a single academic center. Therefore, practice patterns may not be generalizable to other practice settings. Our study had a relatively small sample size, which may have limited the power to detect the association between increased age and screening rates. Also, small sample size could have decreased the robustness of inferences from logistic regression analysis in our study. Another limitation is that data collection was only performed retrospectively via electric medical records at our institution. Therefore, important information, such as DXA performed at outside institutions and over-the-counter use of calcium and vitamin D supplements, may have been missed. Conclusions Osteoporosis screening rates and bone protective treatments prescriptions remain low in men aged 70 years and older. Osteoporosis in men remains underrecognized and undertreated. More research is needed to address specific issues in men, such as the cost-effectiveness of osteoporosis screening and treating older men. Increased awareness about this public health problem among the public and primary care physicians is important to protect musculoskeletal health in men in the United States as the population ages. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. References Adler, R. A. (2006). The need for increasing awareness of osteoporosis in men. Clinical Cornerstone, 8(Suppl. 3), S7-S13. Alswat, K., & Adler, S. M. (2012). Gender differences in osteoporosis screening: Retrospective analysis. Archives of Osteoporosis. Advance online publication. doi: / s Beaupre, L. A., Majumdar, S. R., Dieleman, S., Au, A., & Morrish, D. W. (2012). Diagnosis and treatment of osteoporosis before and after admission to long-term care institutions. Osteoporosis International, 23, doi: / s
5 354 American Journal of Men s Health 7(4) Bliuc, D., Nguyen, N. D., Milch, V. E., Nguyen, T. V., Eisman, J. A., & Center, J. R. (2009). Mortality risk associated with lowtrauma osteoporotic fracture and subsequent fracture in men and women. Journal of the American Medical Association, 301, doi: /jama Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007). Incidence and economic burden of osteoporosis-related fractures in the United States, Journal of Bone and Mineral Research, 22, doi: /jbmr Centers for Medicare & Medicaid Services. (2012). Your Medicare coverage-bone mass measurement (bone density). Retrieved from Cheng, N., & Green, M. E. (2008). Osteoporosis screening for men: Are family physicians following the guidelines? Canadian Family Physician, 54, Lagerlund, M., Sparen, P., Thurfjell, E., Ekbom, A., & Lambe, M. (2000). Predictors of non-attendance in a population-based mammography screening programme; socio-demographic factors and aspects of health behaviour. European Journal of Cancer Prevention, 9, Lewiecki, E. M., Watts, N. B., McClung, M. R., Petak, S. M., Bachrach, L. K., & Shepherd, J. A. (2004). Official positions of the International Society for Clinical Densitometry. Journal of Clinical Endocrinology and Metabolism, 89, doi: /jc Lim, L. S., Hoeksema, L. J., & Sherin, K. (2009). Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. American Journal of Preventive Medicine, 36, doi: /j. amepre Looker, A. C., Melton, L. J., III, Harris, T. B., Borrud, L. G., & Shepherd, J. A. (2010). Prevalence and trends in low femur bone density among older US adults: NHANES compared with NHANES III. Journal of Bone and Mineral Research, 25, doi: /jbmr National Osteoporosis Foundation. (2008). Clinician s guide to prevention and treatment of osteoporosis. Washington, DC: Author. Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Jr., Forciea, M. A., & Owens, D. K. (2008). Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 148, Rao, S. S., Budhwar, N., & Ashfaque, A. (2010). Osteoporosis in men. American Family Physician, 82, Schousboe, J. T., Taylor, B. C., Fink, H. A., Kane, R. L., Cummings, S. R., Orwoll, E. S., & Ensrud, K. E. (2007). Costeffectiveness of bone densitometry followed by treatment of osteoporosis in older men. Journal of the American Medical Association, 298, doi: /jama Shibli-Rahhal, A., Vaughan-Sarrazin, M. S., Richardson, K., & Cram, P. (2011). Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporosis International, 22, doi: /s y U.S. Preventive Services Task Force. (2011). Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 154, doi: / van Staa, T. P., Dennison, E. M., Leufkens, H. G., & Cooper, C. (2001). Epidemiology of fractures in England and Wales. Bone, 29, Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., & Orwoll, E. S. (2012). Osteoporosis in men: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 97, doi: / jc
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationOriginal Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT
Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationNIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.
NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk
More informationNew York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines
New York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines Michael Bauer New York State Department of Health Bureau of Occupational
More informationFactors associated with diagnosis and treatment of osteoporosis in older adults
Osteoporos Int (2009) 20:1963 1967 DOI 10.1007/s00198-008-0831-8 SHORT COMMUNICATION Factors associated with diagnosis and treatment of osteoporosis in older adults S. Nayak & M. S. Roberts & S. L. Greenspan
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationPrevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women
Osteoporos Int (2011) 22:2365 2371 DOI 10.1007/s00198-010-1452-6 ORIGINAL ARTICLE Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women D. Lansdown & B.
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationA Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women
A Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women APHA Conference Washington, DC November 2, 2011 Presenter Disclosures Kathy Schneider, PhD
More informationFactors Associated with Osteoporosis Screening and Recommendations for Osteoporosis Screening in Older Adults
Factors Associated with Osteoporosis Screening and Recommendations for Osteoporosis Screening in Older Adults Smita Nayak, MD 1, Mark S. Roberts, MD, MPP 1 and Susan L. Greenspan, MD 2 1 School of Medicine,
More informationProposed Retirement of Existing Measure for HEDIS 1 : Osteoporosis Testing in Older Women (OTO)
Proposed Retirement of Existing Measure for HEDIS 1 : Osteoporosis Testing in Older Women (OTO) NCQA seeks comments on the proposed retirement of the HEDIS health plan measure Osteoporosis Testing in Older
More informationFactors Associated with Treatment Initiation after Osteoporosis Screening
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 5 Printed in U.S.A. DOI: 10.1093/aje/kwh245 Factors Associated with
More informationAn audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines
Osteoporos Int (2006) 17: 1111 1115 DOI 10.1007/s00198-006-0101-6 SHORT COMMUNICATION An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines R. Baddoura. H. Awada. J. Okais.
More informationOsteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis
Influence of bone densitometry results on the treatment of osteoporosis Nicole S. Fitt, * Susan L. Mitchell, * Ann Cranney, Karen Gulenchyn, Max Huang, * Peter Tugwell Abstract Background: Measurement
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationDisparities in Osteoporosis Screening Between At-Risk African-American and White Women
Disparities in Osteoporosis Screening Between At-Risk African-American and White Women Redonda G. Miller, MD, 1 Bimal H. Ashar, MD, 1 Jennifer Cohen, 1 Melissa Camp, 1 Carmen Coombs, 1 Elizabeth Johnson,
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationOsteoporosis. By Amanda Neilson
Osteoporosis By Amanda Neilson Overview Definition Epidemiology Clinical Aspects Treatments Effects on Exercise Exercise Testing Exercise Prescription Summary and Conclusion References Definition Breakdown
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationDXA Best Practices. What is the problem? 9/29/2017. BMD Predicts Fracture Risk. Dual-energy X-ray Absorptiometry: DXA
BMD Predicts Fracture Risk Ten Year Fracture Probability (%) 50 40 30 20 10 Age 80 70 60 50 E. Michael Lewiecki, MD Director, New Mexico Clinical Research & Osteoporosis Center Director, Bone TeleHealth
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationAppendix B Fracture incidence and costs by province
1 Appendix B Fracture incidence and costs by province Comprehensive, accurate fracture numbers and costs are very important data that could help with prioritization and allocation of health care resources.
More informationIEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan
Policy: IEHP UM Subcommittee Approved Authorization Guidelines IEHP considers bone mineral density testing using DEXA medically necessary for members who meet any of the following criteria: Women aged
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationBone mineral density testing: Is a T score enough to determine the screening interval?
Interpreting Key Trials CME CREDIT EDUCATIONAL OBJECTIVE: Readers will measure bone mineral density at reasonable intervals in their older postmenopausal patients Krupa B. Doshi, MD, CCD Department of
More informationOsteoporosis Physician Performance Measurement Set. October 2006
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More informationScreening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement US
More informationChoice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic
Dan Med J 1/12 December 2014 danish medical JOURNAL 1 Choice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic Katja Thomsen 1,
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationResearch Article Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort
International Journal of Endocrinology Volume 2013, Article ID 715025, 9 pages http://dx.doi.org/10.1155/2013/715025 Research Article Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled
More informationTo understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis.
Nutrition Aspects of Osteoporosis Care and Treatment t Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, OH. Objectives To understand bone growth and development across the lifespan.
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOsteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009
American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationEffect of Precision Error on T-scores and the Diagnostic Classification of Bone Status
Journal of Clinical Densitometry, vol. 10, no. 3, 239e243, 2007 Ó Copyright 2007 by The International Society for Clinical Densitometry 1094-6950/07/10:239e243/$32.00 DOI: 10.1016/j.jocd.2007.03.002 Original
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationClinical Appropriateness Guidelines: Advanced Imaging
Clinical Appropriateness Guidelines: Advanced Imaging Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry Effective Date: September 5, 2017 Proprietary Date of Origin: 05/21/2007
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationFractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases
Financial Disclosures Fractures: Epidemiology and Risk Factors Research grants, speaking or consulting: Amgen, Lilly, Merck, Novartis, Radius Dennis M. Black, PhD Department of Epidemiology and Biostatistics
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Bone Mineral Density Studies sad EFFECTIVE DATE: 06 07 2011 POLICY LAST UPDATED: 11 06 2018 OVERVIEW Bone density studies can be used to identify individuals with osteoporosis and
More informationHIV and your Bones Osteopenia and Osteoporosis
Osteopenia and Osteoporosis Background information For reasons not yet fully understood, higher rates of bone disease are starting to be seen in people living with HIV. These bone diseases include osteopenia
More informationNATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES
NATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES Fact Sheet FY 2007 What is the Mission of the Bone Coalition? The National Coalition for Osteoporosis and Related Bone Diseases is dedicated
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationMeasuring Bone Mineral Density
Measuring Bone Mineral Density Osteoporosis Screening by Pharmacists 9/20/06 Don Downing Institute for Innovative Pharmacy Practice Today s Topics What is osteoporosis? What causes osteoporosis? Screening
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationOfficial Positions on FRAX
196 96 DEPLIANT 3,5x8,5.indd 1 2010 Official Positions on FRAX 21.03.11 11:45 Interpretation and Use of FRAX in Clinical Practice from the International Society for Clinical Densitometry and International
More informationCase identification of patients at risk for an osteoporotic fracture
Identifying Patients With Osteoporosis or at Risk for Osteoporotic Fractures Yong Chen, MD, PhD; Leslie R. Harrold, MD, MPH; Robert A. Yood, MD; Terry S. Field, DSc; and Becky A. Briesacher, PhD Case identification
More informationOsteoporosis and the Burden of Osteoporosis-Related Fractures
n reports n Osteoporosis and the Burden of Osteoporosis-Related Fractures David W. Dempster, PhD Scope of the Problem Osteoporosis, a common bone disease that is characterized by loss of bone mass and
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationVertebral Fracture Assessment with Densitometry
Vertebral Fracture Assessment with Densitometry Policy Number: 6.01.44 Last Review: 12/2018 Origination: 4/2005 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationBone Mineral Density Studies
Bone Mineral Density Studies Policy Number: 6.01.01 Last Review: 3/2019 Origination: 10/1988 Next Review: 3/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for bone
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationOsteoporosis as a Focus for Practice Improvement
Osteoporosis as a Focus for Practice Improvement Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology and Endocrine Sections University of Wisconsin Madison, WI Postmenopausal Osteoporosis
More informationAudit on follow-up of patients with primary Osteoporosis
Abstract Aim: To document the frequency of Dual-energy X- ray absorptiometry (DEXA) scanning and Rheumatology clinic follow-up visits of patients with primary osteoporosis, and compare these with recommended
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationDisclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck
Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Fracture incidence and impact of fractures
More informationComparison of Dietary Supplement Intake between Healthy Individuals and Osteoporosis Patients in Gorgan, Iran
Original Research Article Comparison of Dietary Supplement Intake between Healthy Individuals and Osteoporosis Patients in Gorgan, Iran Mehrdad Aghaei 1, *Samira Eshghinia 2, Sima Seddighi 1, Nafiseh Abdollahi
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationDefining Bone Health and Fracture Risk in West Virginia: The World Health Organization FRAX Assessment Tool
Marshall University Marshall Digital Scholar Orthopaedics Faculty Research Fall 9-2011 Defining Bone Health and Fracture Risk in West Virginia: The World Health Organization FRAX Assessment Tool Franklin
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.gkpublication.in E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Risk Assessment of Osteoporosis in Postmenopausal Women Dr Savita Tamaria
More informationDisclosures Fractures:
Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Research Funding: GlaxoSmithKline, Merck Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Fracture incidence
More informationMedical Policy. MP Vertebral Fracture Assessment With Densitometry
Medical Policy BCBSA Ref. Policy: 6.01.44 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section: Radiology Related Policies 6.01.40 Whole Body Dual X-Ray Absorptiometry to Determine Body Composition
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationPurpose. Methods and Materials
Prevalence of pitfalls in previous dual energy X-ray absorptiometry (DXA) scans according to technical manuals and International Society for Clinical Densitometry. Poster No.: P-0046 Congress: ESSR 2014
More informationBone Density Measurement in Women
Bone Density Measurement in Women Revised 2005 Scope This guideline defines the medical necessity of bone mineral density (BMD) measurement using dualenergy x-ray absorptiometry (DXA or DEXA), and applies
More informationUnderstanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now?
Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now? Steven M. Petak, MD, JD, FACE, FCLM Texas Institute for Reproductive Medicine And Endocrinology, Houston, Texas
More informationWith older women in the United States about 4 times
Bryan Farford, DO; Jonathan Balog, DO; Kensler Dawson Jackson, MD; Daniel Montero, MD Department of Family Medicine (Drs. Farford, Balog, and Jackson); Department of Orthopedic Surgery (Dr. Montero), Mayo
More informationBody Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
International Journal of Public Health Science (IJPHS) Vol.3, No.4, December 2014, pp. 276 ~ 280 ISSN: 2252-8806 276 Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationRisk factors associated with low bone mineral density in Ajman, UAE
Risk factors associated with low bone mineral density in Ajman, UAE Tarek Fawsy 1, Jayadevan Sreedharan 2*, Jayakumary Muttappallymyalil 2, Salma Obaid Saeed Alshamsi 2, Mariyam Saif Salim Humaid Bin Bader
More informationComparison of Bone Density of Distal Radius With Hip and Spine Using DXA
ORIGINAL ARTICLE Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA Leila Amiri 1, Azita Kheiltash 2, Shafieh Movassaghi 1, Maryam Moghaddassi 1, and Leila Seddigh 2 1 Rheumatology
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationInfluence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture
https://doi.org/10.1007/s40520-018-1094-7 ORIGINAL ARTICLE Influence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture Peiwen Wang 1 Yizhong Li 1 Huafeng Zhuang 1 Haiming
More informationWhat Is FRAX & How Can I Use It?
What Is FRAX & How Can I Use It? Jacqueline Osborne PT, DPT Board Certified Geriatric Clinical Specialist Certified Exercise Expert for the Aging Adult Brooks Rehabilitation; Jacksonville, FL Florida Physical
More informationBeyond the T-score: New Thinking in Osteoporosis 2
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/beyond-the-t-score-new-thinking-in-osteoporosis-
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationScreening for absolute fracture risk using FRAX tool in men and women within years in urban population of Puducherry, India
International Journal of Research in Orthopaedics Firoz A et al. Int J Res Orthop. 217 Sep;3(5):151-156 http://www.ijoro.org Original Research Article DOI: http://dx.doi.org/1.1823/issn.2455-451.intjresorthop21739
More informationORIGINAL RESEARCH Underuse and Overuse of Osteoporosis Screening in a Regional Health System: a Retrospective Cohort Study
ORIGINAL RESEARCH Underuse and Overuse of Osteoporosis Screening in a Regional Health System: a Retrospective Cohort Study Anna Lee D. Amarnath, MD, MPH 1,2,4, Peter Franks, MD 1,2, John A. Robbins, MD,
More informationOsteoporosis Update: Keys to Improving Diagnosis and Preventing Fractures
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/spotlight-on/osteoporosis-update-keys-improving-diagnosis-preventingfractures/9812/
More information